Abstract: Provided are a viral vector-based RNA delivery system and a use thereof. The RNA delivery system comprises a viral vector. The viral vector carries an RNA fragment needing to be delivered, and can be enriched in organ tissues of a host. In the host organ tissues, the viral vector can endogenously and spontaneously form a composite structure containing the RNA fragment. The composite structure can enter and bind to target tissues, and feed the RNA fragment into the target tissues. The viral vector has a targeting tag. The composite structure is an exosome. The viral vector RNA delivery system is safe and reliable, and has good druggability and high universality.

Abstract: Provided is a light system, a light element, and a mounting pad of a light. The light system includes a light element and a mounting pad. The light element includes a light-emitting unit to emit light; an attachment unit to attach the light element to any position on a mounting surface on which the light element is mounted; a wireless electric-power receiving unit to receive electric power for driving the light element by wireless electric-power transmission; and a light-emitting unit power supply circuit, connected to the wireless electric-power receiving unit to transmit the electric power received by the wireless electric-power receiving unit to the light-emitting unit. The mounting pad includes a mounting area having the mounting surface on which the light element is mounted and a wireless electric-power transmitting unit to transmit the electric power to the wireless electric-power receiving unit on the mounting surface by wireless electric-power transmission.

Abstract: An RNA delivery system for the treatment of Huntington's disease. The system comprises a viral vector, the viral vector carries RNA fragments capable of treating Huntington's disease, the viral vector is capable of enrichment in organ tissues of a host and endogenously and spontaneously forming a complex containing the RNA fragments capable of treating Huntington's disease in the organ tissues of the host, and the complex can deliver the RNA fragments into a target tissue to treat Huntington's disease. The safety and reliability of the RNA delivery system for the treatment of Huntington's disease have been fully verified. The system has good medicinal properties, strong versatility, and has economic benefits and application prospects.

Abstract: Provided are a gene circuit, an RNA delivery system and the use thereof. Specifically, the gene circuit comprises at least an RNA fragment capable of inhibiting gene expression and/or a targeting tag having a targeting function. The gene circuit can be delivered to a host, enriched in organ tissues of the host and self-assembled to form a complex structure, and inhibits gene expression by means of the RNA fragment, thereby treating diseases. The delivery system comprises the gene circuit and a delivery carrier capable of delivering the gene circuit to organ tissues of a host for enrichment. The provided gene circuit has a targeting function and a treatment function, can quickly and accurately reach target organs and target tissues to exert a treatment effect, and is highly efficient with good results. The safety and reliability of the provided RNA delivery system are fully verified, and the RNA delivery system has good druggability, high universality, and great economic benefits and application prospects.

Abstract: Provided are an RNA plasmid delivery system and an application thereof. The RNA plasmid delivery system comprises a plasmid carrying an RNA fragment required to be delivered; the plasmid can be enriched in an organ tissue of a host, and spontaneously forms an exosome containing the RNA fragment in the organ tissue of the host, and therefore can enter and be combined with a target tissue to deliver the RNA fragment into the target tissue. The RNA delivery system is safe, reliable, good in druggability, and strong in universality.

Abstract: The present disclosure provides a method for improving bioavailability of an NAD+ derivative. The method improves the bioavailability of the NAD+derivative by arranging a CD38 inhibitor and the NAD+ derivative in a same preparation, and controlling the CD38 inhibitor to release first rapidly, and then the NAD+ derivative releases after the CD38 inhibitor has taken effect, thereby increasing the level of NAD+ in vivo.

Abstract: This disclosure relates to bivalent compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the bivalent compounds, and to methods of use the bivalent compounds for the treatment of certain disease in a subject in need thereof. The disclosure also relates to methods for identifying such bivalent compounds.

Abstract: The present application provides a method for detecting a broken fanout wire of a display substrate, and a display substrate, and belongs to the field of display technology. In the method for detecting a broken fanout wire, the display substrate includes a base substrate having first and second surfaces opposite to each other, and a plurality of connection structures disposed at intervals on the first surface; and each connection structure includes first and second pads and a fanout wire electrically connecting the first pad to the second pad. The method for detecting a broken fanout wire includes: forming at least one detection unit, which includes: connecting at least two connection structures in series through a connecting part; and measuring a head and an end of the detection unit to obtain resistance of the detection unit, and determining whether there is a broken fanout wire in the detection unit.

Abstract: Provided in the embodiments of the present disclosure are a display panel, a display apparatus and a driving method therefor, and an image rendering method.

Abstract: Transcription factors (TFs) represent a major class of therapeutic targets for the treatment of human diseases including cancer. Although the biological function and even crystal structure of many TFs have been clearly elucidated, there is still no viable approach to target the majority of TFs, thus rendering them undruggable for decades. PROTACs (PROteolysis TArgeting Chimeras) have emerged as a powerful tool for the pharmaceutical development since the effect of PROTACs largely relies on engineered protein-protein interaction to aid the degradation of targets by the ubiquitin-proteasome system (UPS). The present disclosure provides a DNA-PROTAC platform for targeted degraders of individual TFs of interest. These DNA based Transcription Factor targetting PROTACS (or “TF-PROTACS”) may provide specificity to TF degradation based on the conserved DNA-binding motifs of respective TFs.

Abstract: Provided are a surface zwitterionized silicone antifouling coating and a preparation method thereof. In the disclosure, hydroxyl-terminated polydimethylsiloxane and N-aminoethyl-3-aminopropyl methyl dimethoxysilane are used as raw materials, and tetramethylammonium hydroxide pentahydrate is used as a catalyst, thereby preparing a series of polydimethylsiloxane resins containing amino side chains in different proportions; then side chain amino modified polydimethylsiloxane is crosslinked and cured by using 3-glycidyloxypropyltrimethoxysilane as a curing agent; after that, the cured silicone coating is soaked in a solution of 1,3-propane sultone in acetone for ionization.

Abstract: In some embodiments of the present disclosure, a sustained release osmotic-controlled pharmaceutical composition is provided, including: a core and a semi-permeable membrane coated on the core. The core includes a drug compartment, in which the drug compartment includes a first active ingredient, a first polymer and a first osmogen, and the first active ingredient includes lurasidone, a pharmaceutical acceptable salt of the lurasidone or a combination thereof. The semi-permeable membrane includes a membrane body and at least one pore distributed in the membrane body.

Abstract: Techniques for generating a test case involve: acquiring a first set of coding sequences representing a first set of test cases selected from a test case set for product testing. A test element in a test case of the test case set is coded based on the position of the test element in the element hierarchy of the test case set. The techniques further involve: generating a second set of coding sequences by performing a random variation related to at least one test element with respect to the first set of coding sequences; and generating a second set of test cases based on the second set of coding sequences. Accordingly, product testing and development may be automated, and the case set may change dynamically in a way that is adapted to product development while significantly reducing the overhead of designing and reviewing test cases throughout the product life cycle.

Abstract: A lighting assembly and a lighting device are provided. The lighting assembly is U-shaped and includes a radiator, a light-emitting plate and a connector. The radiator is provided with a rotating groove and an avoidance notch communicated with the rotating groove. The rotating groove is provided on the inner side of the radiator, and the avoidance notch extends from the rotating groove to the edge of the radiator. The light-emitting plate is provided on the radiator and includes a plurality of light-emitting diode (LED) lamps in parallel and/or in series. The connector includes a first connecting part and a second connecting part. The first connecting part is configured to be connected to a free end of a telescopic assembly, and the second connecting part is placed in the rotating groove. The avoidance notch provides a space for the movement of the first connecting part.

Abstract: The invention provides a method for preparing pyrrolidone, and the invention provides a method for catalytically preparing pyrrolidone with ?-aminobutyric acid in the presence of carnitine-CoA ligase CaiC. The carnitine-CoA ligase CaiC has an amino acid sequence as shown in SEQ ID NO:1. The ligase has catalytic activity in the cyclization of ?-aminobutyric acid to produce pyrrolidone. The carnitine-CoA ligase provided in the present invention affords a yield of pyrrolidone of 3.26 g/L and a molar yield of 39.53% in 24 h when ?-aminobutyric acid is used as a substrate, thus reducing the production period, improving the production of pyrrolidone, and accelerating the industrialization process of producing pyrrolidone by enzymatic conversion method.

Abstract: A communication method and apparatus. A terminal device determines channel state information based on S indexes of S vectors. Each of the S vectors is included in a first vector quantization dictionary. The first vector quantization dictionary includes N1 vectors, where N1 and S are both positive integers. The terminal device sends the channel state information to a network device. Because a vector included in the vector quantization dictionary usually has a relatively large dimension, quantizing channel information by using the first vector quantization dictionary is equivalent to performing dimension expansion on the channel information or maintaining a relatively high dimension. High-precision feedback is implemented by using relatively low signaling overheads.

Abstract: The present disclosure provides a kit and method for constructing a long-acting depression animal model. The present disclosure adopts Bacille Calmette-Guerin (BCG) (or Mycobacterium bovis (M bovis)) and low-dose pertussis toxin (PTX) for combined induction, which greatly reduces modeling cost. A mouse model constructed by the method of the present disclosure can clearly distinguish a time interval of pathological behaviors from a time interval of depression-like behaviors and has prominent face validity and predictive validity. The method of the present disclosure is simple and convenient and does not require a large number of tedious daily operations as the depression model construction by chronic unpredictable stress, chronic restraint stress, social defeat, mother-child separation, or the like. The mouse model of the present disclosure can provide a valuable long-term intervention window for research on antidepressant therapy.

Abstract: Various aspects of the present disclosure generally relate to wireless communication. In some aspects, a user equipment (UE) may receive, from a network entity, a configuration of at least one sounding reference signal (SRS) resource, wherein the configuration indicates a pseudo-random sequence for muting an SRS associated with the at least one SRS resource. The UE may transmit the SRS using the at least one SRS resource based at least in part on the pseudo-random sequence. Numerous other aspects are described.

Abstract: The present invention relates to a platform door control apparatus based on a double 2-vote-2 architecture, including a security communication and logic processing module, a driver collection module, and a maintenance module, the security communication and logic processing module is separately connected to the driver collection module and the maintenance module, and both the security communication and logic processing module and the driver collection module are devices using the double 2-vote-2 architecture. Compared with the prior art, the present invention has the following advantages of effectively improving linkage efficiency of a signal system and a platform door system, and the like.

Abstract: To automate time series forecasting machine learning pipeline generation, a data allocation size of time series data may be determined based on one or more characteristics of a time series data set. The time series data may be allocated for use by candidate machine learning pipelines based on the data allocation size. Features for the time series data may be determined and cached by the candidate machine learning pipelines. Predictions of each of the candidate machine learning pipelines using at least the one or more features may be evaluated. A ranked list of machine learning pipelines may be automatically generated from the candidate machine learning pipelines for time series forecasting based upon evaluating predictions of each of the one or more candidate machine learning pipelines.